Stock Analysis

3 European Stocks Estimated To Be Undervalued By Up To 44.8%

OB:BRG
Source: Shutterstock

As European markets show signs of recovery, bolstered by the European Central Bank's interest rate cuts and a delay in higher tariffs, investors are keenly observing opportunities that may arise from these developments. In such an environment, identifying stocks that are potentially undervalued can be crucial for investors looking to capitalize on market movements while considering factors like economic policy shifts and trade uncertainties.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In Europe

NameCurrent PriceFair Value (Est)Discount (Est)
Cenergy Holdings (ENXTBR:CENER)€8.42€16.4948.9%
BFF Bank (BIT:BFF)€7.50€14.3947.9%
Mips (OM:MIPS)SEK352.60SEK690.3448.9%
LPP (WSE:LPP)PLN15610.00PLN30721.8649.2%
Lindab International (OM:LIAB)SEK186.80SEK372.0949.8%
TF Bank (OM:TFBANK)SEK345.50SEK683.3349.4%
Verbio (XTRA:VBK)€9.24€18.2549.4%
Stille (OM:STIL)SEK209.00SEK400.6247.8%
Komplett (OB:KOMPL)NOK11.50NOK22.8149.6%
Fodelia Oyj (HLSE:FODELIA)€7.14€13.9148.7%

Click here to see the full list of 172 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Almirall (BME:ALM)

Overview: Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across multiple regions including Spain, Europe, the Middle East, the United States, Asia, and Africa with a market cap of approximately €2 billion.

Operations: The company's revenue segments include €97.23 million from commercial areas through licensees, €808.38 million from its own network in Europe, and €55.43 million from its own network in the United States.

Estimated Discount To Fair Value: 39%

Almirall is trading at €9.37, significantly below its estimated fair value of €15.37, suggesting it may be undervalued based on cash flows. The company's revenue is expected to grow 9.5% annually, outpacing the Spanish market's 5% growth rate, with earnings forecasted to increase by 35.8% per year over the next three years. Recent profitability and executive changes indicate a strategic focus on maintaining growth momentum in medical dermatology across Europe.

BME:ALM Discounted Cash Flow as at Apr 2025
BME:ALM Discounted Cash Flow as at Apr 2025

Borregaard (OB:BRG)

Overview: Borregaard ASA develops, produces, and markets specialized biochemicals and biomaterials globally with a market cap of NOK16.53 billion.

Operations: The company's revenue segments consist of Bio Materials at NOK2.62 billion, Bio Solutions at NOK4.24 billion, and Fine Chemicals at NOK799 million.

Estimated Discount To Fair Value: 37.2%

Borregaard is trading at NOK 165.8, well below its estimated fair value of NOK 264.17, highlighting potential undervaluation based on cash flows. The company's earnings are forecast to grow at 14% annually, surpassing the Norwegian market's growth rate of 7.8%. Recent financial results show a year-over-year increase in fourth-quarter sales and net income, while the full-year net income slightly declined compared to the previous year.

OB:BRG Discounted Cash Flow as at Apr 2025
OB:BRG Discounted Cash Flow as at Apr 2025

Byggmax Group (OM:BMAX)

Overview: Byggmax Group AB (publ) operates in the sale of building materials and related products for DIY projects across Sweden, Norway, and internationally, with a market cap of SEK2.85 billion.

Operations: The company generates revenue primarily from its Byggmax segment, which accounts for SEK6.07 billion.

Estimated Discount To Fair Value: 44.8%

Byggmax Group is trading at SEK 48.65, significantly below its estimated fair value of SEK 88.15, indicating potential undervaluation based on cash flows. Earnings are projected to grow substantially at 52.24% annually over the next three years, outpacing the Swedish market's growth rate of 13.1%. Recent earnings reports show a reduction in net loss for Q1 2025 compared to the previous year, with revenue increasing from SEK 872 million to SEK 944 million year-over-year.

OM:BMAX Discounted Cash Flow as at Apr 2025
OM:BMAX Discounted Cash Flow as at Apr 2025

Key Takeaways

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Borregaard might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About OB:BRG

Borregaard

Engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally.

Flawless balance sheet with reasonable growth potential and pays a dividend.

Advertisement